PD-1 inhibitors for urothelial cancer: combination or sequential therapy?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1 inhibitors for urothelial cancer: combination or sequential therapy?

Published:2020-12 Issue:10267 Volume:396 Page:1977
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Zhang Sheng,Li Wenfeng

Publisher

Elsevier BV

Subject

General Medicine

Reference3 articles.

1. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial;Galsky;Lancet,2020

2. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Eng J Med,2017

3. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer;Galsky;J Clin Oncol,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity;International Immunopharmacology;2024-12

2. Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder;Asia-Pacific Journal of Clinical Oncology;2023-07-17

3. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response;Signal Transduction and Targeted Therapy;2022-09-19

4. Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further;Journal of Clinical Oncology;2022-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3